Clinical-stage Biopharmaceutical Company Granted Major European Patent

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company dedicated to developing innovative ocular therapies, has recently announced the grant of a significant European patent. This patent, titled “Compositions Comprising Chemerin Analogs and Methods of Use,” covers the company's novel OK-101 chemerin analogs. This development marks a crucial milestone for OKYO Pharma as it strengthens its intellectual property portfolio in the treatment of inflammatory dry eye disease (DED) and other anterior ocular segment diseases, including neuropathic corneal pain (NCP). $OKYO Pharma (OKYO.US)$